USE OF CYCLOPAMINE IN THE TREATMENT OF BASAL CELL CARCINOMA AND OTHER TUMORS

• US 20100048725A2
• Filed: 10/09/2003
• Published: 02/25/2010
• Est. Priority Date: 07/02/2001
• Status: Active Grant

• Current Assignee: Sinan Tas
• Original Assignee: Sinan Tas
• Inventors: Tas, Sinan, Avci, Oktay
• Granted Patent: US 7,893,078 B2
• Time in Patent Office: Days
• US Class Current: 514/659
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 8/63 Steroids; Derivatives thereof
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61Q 19/02 for chemically bleaching or whitening the skin

Abstract

This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC'"'"'s) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC'"'"'s and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis.

Claims

1-43. -43. (canceled)

44. A method for inducing apoptosis of tumor cells in a tumor-bearing patient, comprising

determining that Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of tumor cells and

administering to the patient cyclopamine or a pharmaceutically acceptable salt thereof in a dose that is sufficient to induce apoptosis of said tumor cells and to cause decrease of size or disappearance of the tumor.

45. A method for treatment of a patient having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of the tumor cells, comprising

administering to the patient a medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

46. The method according to claim 45, characterized in that a dose sufficing to induce apoptosis of the tumor cells causes a smaller proportion of normal tissue cells or no normal tissue cells to undergo apoptosis.

49. The method according to any one of claims 45 to 48, wherein said another compound that selectively inhibits Hedgehog/Smoothened signaling is a compound that binds to the same biological target as cyclopamine to exert said inhibition.

50. The method according to any one of claims 45 to 48, wherein said another compound that selectively inhibits Hedgehog/Smoothened signaling is a derivative of cyclopamine.

51. The method according to any one of claims 45 to 48, wherein said medicament is a pharmaceutical composition selected from the group of compositions for topical, non-topical or systemic administration.

52. The method according to claim 51, characterized in that the composition for non-topical or systemic administration is in the form of an aqueous solution.

53. The method according to claim 51, characterized in that the composition for non-topical or systemic administration is in the form of liposomes, having cyclopamine or said another compound entrapped therein.

54. The method according to claim 51, characterized in that the non-topical administration is direct intratumoral injection.

55. The method according to claim 51, characterized in that cyclopamine or said another compound is in a pharmaceutical form enabling controlled release.

56. The method according to claim 51, characterized in that cyclopamine or said another compound is adsorbed onto a dermal patch.

57. The method according to claim 51, characterized in that said medicament is in the form of a cream or ointment or a gel or a hydrogel.

47. A method for treatment of a patient having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of differentiation and for inhibition of apoptosis of tumor cells, comprising

administering to the patient a medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce differentiation and apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

48. The method according to claim 47, characterized in that a dose sufficing to induce differentiation and apoptosis of the tumor cells causes a smaller proportion of normal tissue cells or no normal tissue cells to undergo differentiation and apoptosis.

58. A medicament comprising cyclopamine or a pharmaceutically acceptable salt thereof or another compound that selectively inhibits Hedgehog/Smoothened signaling with instructions for effective administration to cause decrease of size or disappearance of a tumor wherein Hedgehog/Smoothened signaling is utilized to prevent apoptosis of the tumor cells and said administration induces apoptosis of the tumor cells to cause decrease of size or disappearance of the tumor.

59. A medicament as in claim 58, wherein said another compound is a derivative of cyclopamine.

60. A method for treatment of a human subject having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of the tumor cells, comprising

administering to the subject a medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

68. A method according to claim 60, wherein the tumor is a skin tumor and said medicament is formulated for intratumoral or topical or systemic administration.

69. A method according to claim 60, wherein said tumor is basal cell carcinoma or trichoepithelioma or a melanocytic tumor.

70. A method according to claim 69, wherein said medicament is a formulation comprising cyclopamine or a pharmaceutically applicable salt thereof and is topically applied onto the tumor about four times or more per day to deliver about 3.6 micromole or more of cyclopamine per day to each square centimeter of the surface area of the tumor on skin.

71. A method according to claim 70, wherein said medicament is in the form of a cream of cyclopamine.

61. A method for treatment of a human subject having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of the tumor cells, comprising

administering to the subject a medicament comprising cyclopamine or another compound that inhibits Hedgehog/Smoothened signaling by binding to the same biological target to which cyclopamine binds to inhibit Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

62. A method for treatment of a human subject having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of differentiation and for inhibition of apoptosis of the tumor cells, comprising

administering to the subject a medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce differentiation and apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

63. A method for treatment of a human subject having a tumor wherein Hedgehog/Smoothened signaling is utilized for inhibition of differentiation and for inhibition of apoptosis of the tumor cells, comprising

administering to the subject a medicament comprising cyclopamine or another compound that inhibits Hedgehog/Smoothened signaling by binding to the same biological target to which cyclopamine binds to inhibit Hedgehog/Smoothened signaling,

wherein said medicament is administered in a dose that is sufficient to induce differentiation and apoptosis of said tumor cells and causes decrease of size or disappearance of the tumor.

64. A medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

with instructions for effective administration to a tumor-bearing human subject for causation of decrease of size or disappearance of the tumor,

wherein Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of the tumor cells and said administration induces apoptosis of the tumor cells and causes decrease of size or disappearance of the tumor.

65. A medicament comprising cyclopamine or another compound that inhibits Hedgehog/Smoothened signaling by binding to the same biological target to which cyclopamine binds to inhibit Hedgehog/Smoothened signaling,

with instructions for effective administration to a tumor-bearing human subject for causation of decrease of size or disappearance of the tumor,

wherein Hedgehog/Smoothened signaling is utilized for inhibition of apoptosis of the tumor cells and said administration induces apoptosis of the tumor cells and causes decrease of size or disappearance of the tumor.

66. A medicament comprising cyclopamine or another compound that selectively inhibits Hedgehog/Smoothened signaling,

with instructions for effective administration to a tumor-bearing human subject for causation of decrease of size or disappearance of the tumor,

wherein Hedgehog/Smoothened signaling is utilized for inhibition of differentiation and for inhibition of apoptosis of the tumor cells and said administration induces differentiation and apoptosis of the tumor cells and causes decrease of size or disappearance of the tumor.

67. A medicament comprising cyclopamine or another compound that inhibits Hedgehog/Smoothened signaling by binding to the same biological target to which cyclopamine binds to inhibit Hedgehog/Smoothened signaling,

with instructions for effective administration to a tumor-bearing human subject for causation of decrease of size or disappearance of the tumor,

wherein Hedgehog/Smoothened signaling is utilized for inhibition of differentiation and for inhibition of apoptosis of the tumor cells and said administration induces differentiation and apoptosis of the tumor cells and causes decrease of size or disappearance of the tumor.